Drug Profile


Alternative Names: BIBW 2992 MA2; BIBW-2992; Gilotrif; Giotrif; Tomtovok; Tovok; Xovoltib

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Boehringer Ingelheim
  • Developer Boehringer Ingelheim; European Organisation for Research and Treatment of Cancer; European Thoracic Oncology Platform; H. Lee Moffitt Cancer Center and Research Institute
  • Class Antineoplastics; Quinazolines; Radiation-sensitising agents; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists; ERBB 4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer; CNS cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer
  • Phase III Breast cancer; Head and neck cancer
  • Phase II Glioma; Urogenital cancer
  • Phase I Glioblastoma; Rhabdomyosarcoma; Solid tumours
  • No development reported Colorectal cancer; Prostate cancer

Most Recent Events

  • 21 Mar 2017 Phase-II clinical trials in Head and neck cancer (Second-line therapy or greater, Combination therapy, Metastatic disease, Recurrent) in USA (PO) (NCT02979977)
  • 01 Mar 2017 Boehringer Ingelheim completes the phase III LUX-Lung-3 trial in Non-small cell lung cancer (First-line therapy, Late-stage disease) in Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, France, Germany, Hong Kong, Ireland, Italy, Japan, South Korea, Malaysia, Peru, Philippines, Romania, Russia, Taiwan, Thailand, Ukraine, United Kingdom and USA (NCT00949650)
  • 01 Mar 2017 Registered for Non-small cell lung cancer (EGFR mutation-positive, First-line therapy, Late-stage disease) in China (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top